Shots:
- QurCan Therapeutics has entered into an exclusive research & collaboration agreement with Eli Lilly for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS)
- Lilly & QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicines for CNS & PNS delivery, with QurCan optimizing candidates via its TERP platform
- Lilly will lead research, clinical development & commercialization, while QurCan will receive an upfront payment & strategic investment, plus research support & ~$237M/program in milestones, and tiered royalties on global net sales
Ref: Businesswire | Image: QurCan & Eli Lilly | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
